• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
  • About Us
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us

Poster: T cell Epitope Content Comparison (EpiCC) of swine H1 influenza A virus hemagglutinin to identify best vaccine match

by Elena Iemma | Jan 8, 2024

H1N1 G4 swine influenza T cell epitope analysis in swine and human vaccines and circulating strains uncovers potential risk to swine and humans

H1N1 G4 swine influenza T cell epitope analysis in swine and human vaccines and circulating strains uncovers potential risk to swine and humans

by Elena Iemma | Oct 26, 2022

Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetii Immunity

Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetii Immunity

by Elena Iemma | May 24, 2022

Development of a Novel Fully Functional Coagulation Factor VIII with Reduced Immunogenicity Utilizing an In silico Prediction and Deimmunization Approach

Development of a Novel Fully Functional Coagulation Factor VIII with Reduced Immunogenicity Utilizing an In silico Prediction and Deimmunization Approach

by Elena Iemma | Jun 8, 2021

Identification, Selection and Immune Assessment of Liver Stage CD8 T Cell Epitopes From Plasmodium falciparum

Identification, Selection and Immune Assessment of Liver Stage CD8 T Cell Epitopes From Plasmodium falciparum

by Elena Iemma | Jun 8, 2021

« Older Entries

Recent Posts

  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy 
  • BEBPA Workshop: Streamlining Immunogenicity Assessment of Host Cell Proteins
  • Advancing Immunogenicity Science: EpiVax in 2025 
  • EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.